The Cyber Resilience Act forces a security reset for connected device makers

Tern plc

The EU Cyber Resilience Act introduces mandatory cybersecurity requirements for products with digital elements sold within the European Union, moving security obligations from guidance to enforceable regulation. For manufacturers of connected devices, embedded systems and industrial equipment, this represents a structural shift in how products must be designed, maintained and documented across their entire lifecycle.

The Act requires demonstrable security by design, secure default configurations, structured vulnerability handling and controlled software updates. Importantly, it also requires evidence. Companies must not only implement technical safeguards but also maintain documentation and processes that withstand regulatory scrutiny. This has implications for engineering resources, certification timelines and ongoing support costs.

Compliance is not a single event but an operational capability that must be embedded into product development and fleet management. Firms that delay implementation may face compressed delivery schedules, increased remediation costs or restricted market access. Those that prepare early can integrate compliance into standard operating processes and reduce disruption.

A central requirement of the Act is secure lifecycle management. Devices must be provisioned securely, authenticated reliably and updated safely throughout their operational life. Many legacy provisioning models rely on static credentials or manual processes that are difficult to scale and audit. Under the new framework, these approaches may expose companies to compliance gaps.

Device Authority positions its platform around automated device identity management, dynamic credential provisioning and policy enforcement. By embedding cryptographic identities into devices at scale and managing them throughout their lifecycle, manufacturers can create a structured control framework aligned with regulatory expectations. Automation reduces reliance on manual intervention and improves consistency across large device estates.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search